Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Krell

Showing results (1-10 of 135) with videos related to

Pageof 14
Sort By:
The Lancet. Oncology|March 3, 2012
Ginger: the root of cancer therapy?Jonathan Krell, Justin Stebbing
The Lancet. Oncology|June 9, 2012
Circulating tumour cells as biomarkers in early breast cancerJonathan Krell, Justin Stebbing
The Lancet. Oncology|May 5, 2012
Coffee: the science and art of moderationJonathan Krell, Justin Stebbing
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2014
Broader implications of a stage-guided stratified therapeutic approach for AIDS-related Kaposi's sarcomaJonathan Krell, Justin Stebbing
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2014
Reply to S.E. Krown et alJonathan Krell, Justin Stebbing
The Lancet. Oncology|September 3, 2013
Reforms in the English National Health Service: the voluntary sector in cancer care provisionJonathan Krell, Jonathan Waxman
Future Oncology (London, England)|August 17, 2012
Cancer vaccines: is prevention better than cure?Adam E Frampton, Jonathan Krell
Current Oncology Reports|January 9, 2024
Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid TumoursNina Fuller-Shavel, Jonathan Krell
European Journal of Cancer (Oxford, England : 1990)|May 10, 2011
The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?Costi Alifrangis, Jonathan Krell, Justin Stebbing
BMC Cancer|April 5, 2012
The clinical significance of tumor infiltrating lymphoctyes in breast cancer: does subtype matter?Jonathan Krell, Adam E Frampton, Justin Stebbing
Pageof 14

Showing results (1-10 of 135) with videos related to

Sort By:
Pageof 14
The Lancet. Oncology|March 3, 2012
Ginger: the root of cancer therapy?Jonathan Krell, Justin Stebbing
The Lancet. Oncology|June 9, 2012
Circulating tumour cells as biomarkers in early breast cancerJonathan Krell, Justin Stebbing
The Lancet. Oncology|May 5, 2012
Coffee: the science and art of moderationJonathan Krell, Justin Stebbing
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2014
Broader implications of a stage-guided stratified therapeutic approach for AIDS-related Kaposi's sarcomaJonathan Krell, Justin Stebbing
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2014
Reply to S.E. Krown et alJonathan Krell, Justin Stebbing
The Lancet. Oncology|September 3, 2013
Reforms in the English National Health Service: the voluntary sector in cancer care provisionJonathan Krell, Jonathan Waxman
Future Oncology (London, England)|August 17, 2012
Cancer vaccines: is prevention better than cure?Adam E Frampton, Jonathan Krell
Current Oncology Reports|January 9, 2024
Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid TumoursNina Fuller-Shavel, Jonathan Krell
European Journal of Cancer (Oxford, England : 1990)|May 10, 2011
The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?Costi Alifrangis, Jonathan Krell, Justin Stebbing
BMC Cancer|April 5, 2012
The clinical significance of tumor infiltrating lymphoctyes in breast cancer: does subtype matter?Jonathan Krell, Adam E Frampton, Justin Stebbing
Pageof 14